Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00047762
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2002-10-16
Brief Title:
Safety Efficacy and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
Open-Label Multicenter Dose-Escalation Study in Subjects wAdvanced Colorectal Cancer to Evaluate the Safety Efficacy and Pharmacokinetics of Tarceva in Combination w5-Fluorouracil Leucovorin and Irinotecan and of Bevacizumab in Combination wTarceva 5-Fluorouracil Leucovorin and Irinotecan
Status:
COMPLETED
Status Verified Date:
2004-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is test the safety of Tarceva find the best dose and see what effects good and bad it has on you and your colorectal cancer The effects of Tarceva will be evaluated in combination with 5-fluorouracil leucovorin and irinotecan with or without Bevacizumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None